Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

Blood

Volumn 116, Issue 23, 2010, Pages 4916-4925

  Ott, German ^a,b   Ziepert, Marita ^c   Klapper, Wolfram ^d   Horn, Heike ^b   Szczepanowski, Monika ^d   Bernd, Heinz Wolfram ^e   Thorns, Christoph ^e   Feller, Alfred C ^e   Lenze, Dido ^f   Hummel, Michael ^f   Stein, Harald ^f   Müller Hermelink, Hans Konrad ^a   Frank, Matthias ^g   Hansmann, Martin Leo ^g   Barth, Thomas F E ^h   Möller, Peter ^h   Cogliatti, Sergio ⁱ   Pfreundschuh, Michael ^j   Schmitz, Norbert ^k   Trümper, Lorenz ^l   Loeffler, Markus ^c   Rosenwald, Andreas ^a   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^j SAARLAND UNIVERSITY   (Germany)

^k DEPARTMENT OF CARDIOLOGY   (Germany)

^l UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; LEUKOCYTE ANTIGEN; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CLASSIFIER; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ALGORITHM; GENETIC PREDISPOSITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TREATMENT RESPONSE;

EID: 78649742465     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-276766     Document Type: Article

References (36)

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511. (Pubitemid 30082188)
3. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
4. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005; 105(5):1851-1861.
5. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.
6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.
7. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-12.
8. de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol. 2009;62(2): 128-138.
9. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
10. Feller AC, Diebold J. Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas (Based on the WHO Classification). New York, NY: Springer Verlag; 2004.
11. Lennert K, Feller A. Histopathology of Non-Hodgkin's Lymphomas. New York, NY: Springer Verlag; 1992.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Fleiss JL. Measuring normal scale agreement among many raters. Psych Bull. 1971;76: 378-382.
14. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18(8):1113-1120.
15. Haarer CF, Roberts RA, Frutiger YM, et al. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med. 2006;130(12):1819-1824.
16. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208(5):714-723.
17. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109(11): 4930-4935.
18. Sjo LD, Poulsen CB, Hansen M, et al. Profiling of diffuse large B-cell lymphoma by immunohis tochemistry: identification of prognostic subgroups. Eur J Haematol. 2007;79(6):501-507. (Pubitemid 350126679)
19. van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poorrisk diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(25):4135-4142.
20. Amen F, Horncastle D, Elderfield K, et al. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology. 2007;51(1): 70-79.
21. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003; 101(1):78-84.
22. de Paepe P, Achten R, Verhoef G, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol. 2005;23(28):7060-7068.
23. Dupuis J, Gaulard P, Hemery F, et al. Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica. 2007;92(6):778-783.
24. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26(3):447-454.
25. Veelken H, Vik DS, Schulte Moenting J, et al. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol. 2007; 18(5):931-939.
26. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594.
27. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009;100(10):1842-1847.
28. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16): 2717-2724.
29. Bernd HW, Ziepert M, Thorns C, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. Haematologica. 2009;94(11):1569-1580.
30. Engelhard M, Brittinger G, Huhn D, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997; 89(7):2291-2297.
31. Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma. 2002;43(1):97-104. (Pubitemid 34223976)
32. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279-4284.
33. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107(11): 4207-4213.
34. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106(9):3183-3190.
35. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-9.
36. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.